| Catalog No. | VK515016 |
|---|
| Description | Diridavumab, the alternative name, CR6261, is a human monoclonal antibody directed against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a Dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants). |
|---|
| Species reactivity | Influenza A virus |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG1, lambda |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
HA/Hemagglutinin |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P03455 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | CR-6261, CR6261, 1393659-46-5 |
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
